Clearing away neurodegenerative disease

PRECISION MEDICINE TO PRESERVE NEURONS

Caraway Therapeutics is an emerging biopharmaceutical company pursuing novel approaches for the treatment of debilitating neurodegenerative diseases by preserving neurons. It is a leader in the cutting-edge science of activating cellular recycling processes to clear toxic materials and defective cellular components (autophagy), an exciting new focus for potential therapeutics. Caraway has a rigorous, scientific product engine with multiple approaches, using genetically defined targets to find potential treatments related to these processes.

Urgent, Unmet Medical Need

Targeted Approach

Leveraging Advances in Neuroscience

Neurodegenerative diseases represent an urgent and expanding unmet medical need. Caraway’s approach to developing targeted treatments leverages the body’s natural ability to identify toxic cellular materials and enhances their clearance, preventing loss of neurons. By increasing lysosomal flux, Caraway’s small molecules can stimulate clearance of dysfunctional cellular components.

News

October 10, 2019

Rheostat Therapeutics Announces Rebrand to Caraway Therapeutics and New Kendall Square Office

November 26, 2018

Rheostat Therapeutics Announces $23 Million Series A Financing To Develop Potential Treatments for Neurodegenerative Diseases

Our Team

Solutions to complex problems require an unique combination of rigor and creativity. The Caraway team drives our development programs forward by bringing passion and precision to our work every day.